Publikationen in Zusammenarbeit mit Forschern von Hospital Vall d'Hebron (84)

2023

  1. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment

    European Journal of Surgical Oncology, Vol. 49, Núm. 10

2022

  1. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

  2. Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

    BMC Cancer, Vol. 22, Núm. 1

2021

  1. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

    European Journal of Cancer, Vol. 152, pp. 68-77

  2. Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments

    Journal of Surgical Oncology, Vol. 123, Núm. 1, pp. 71-79

  3. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    npj Breast Cancer, Vol. 7, Núm. 1

  4. The ESSO core curriculum committee update on surgical oncology

    European Journal of Surgical Oncology, Vol. 47, Núm. 11, pp. e1-e30

  5. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. A randomized study comparing different doses of superparamagnetic iron oxide tracer for sentinel lymph node biopsy in breast cancer: The SUNRISE study

    European Journal of Surgical Oncology, Vol. 46, Núm. 12, pp. 2195-2201

  2. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

  3. Axillary staging based on molecular analysis: Results of the B-CLOSER-II study

    Pathology Research and Practice, Vol. 216, Núm. 11

  4. Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

    Frontiers in Oncology, Vol. 10

  5. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

  6. Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial

    Journal of Clinical Oncology, Vol. 38, Núm. 11, pp. 1186-1197

2019

  1. Learning curves in intraoperative ultrasound guided surgery in breast cancer based on complete breast cancer excision and no need for second surgeries

    European Journal of Surgical Oncology, Vol. 45, Núm. 4, pp. 578-583

  2. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement

    Oncologist, Vol. 24, Núm. 5, pp. 603-611

  3. Percutaneous ultrasound-guided vacuum-assisted excision of benign breast lesions: A learning curve to assess outcomes

    British Journal of Radiology, Vol. 92, Núm. 1094

2018

  1. A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer

    Clinical Breast Cancer, Vol. 18, Núm. 4, pp. e613-e619

  2. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  3. Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

    Annals of Oncology, Vol. 29, Núm. 2, pp. 405-417